Latest News
AN2 Therapeutics, Inc.
- AN2 Therapeutics to Present Phase 2 Design for Epetraborole in Polycythemia Vera at the 18
- AN2 Therapeutics to Participate at Upcoming Investor Conferences
- Form 4 AN2 Therapeutics Inc: Patricia A. Martin (Director) For: 12 October
- Cash pay becomes 389 shares for AN2 Therapeutics (ANTX) director Patricia A. Martin.
- Shares replace cash pay as AN2 Therapeutics (ANTX) director receives 2,465 shares.
- AN2 Therapeutics Director Patricia A. Martin Acquires 389 Shares at No Cost
- AN2 Therapeutics (ANTX) Falls 9.63% to $5.07, Testing Key Support - MAMA Signal
- AN2 Therapeutics Secures Extended Gates Foundation Funding For GSK Tuberculosis Collaboration
- AN2 Therapeutics Announces Extension of Funding for Tuberculosis Research Collaboration with GSK
- Gates Foundation Extends Funding for AN2 Therapeutics, GSK Research Collab
- AN2 Therapeutics Gets Gates Foundation Funding Extension for Tuberculosis Research
- AN2 Therapeutics Extends Tuberculosis Research Collaboration With GSK With Gates Foundation Funding
Headlines from the last 30 days, linking to the original publishers. See all market news →